The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms

References

• Campbell PJ, Green AR. Mechanisms of disease. The myeloproliferative disorders. N Engl J Med. 2006;355:2452–2466.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–3225.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Chronic inflammation as a promoter of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37:214–220.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res. 2013;38:263–266.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev. 2013;24:133–145.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Bjørn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:102476.
   PubMed Web of Science ®Google Scholar
• Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediators Inflamm. 2015;2015:145293.
   PubMed Web of Science ®Google Scholar
• Mondet J, Hussein K, Mossuz P. Circulating cytokine levels as markers of inflammation in Philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest. Mediators Inflamm. 2015;2015:670580.
   PubMed Web of Science ®Google Scholar
• Koschmieder S, Mughal TI, Hasselbalch HC, et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30:1018–1024.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356–1363.
   PubMed Web of Science ®Google Scholar
• Vaidya R, Gangat N, Jimma T, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87:1003–1005.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Finke C, Abdelrahman RA, et al. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol. 2013;88:312–316.
   PubMed Web of Science ®Google Scholar
• Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep. 2014;9:331–339.
   PubMed Web of Science ®Google Scholar
• Skov V, Larsen TS, Thomassen M, et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol. 2011;87:54–60.
   PubMed Web of Science ®Google Scholar
• Skov V, Thomassen M, Riley CH, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol. 2012;40:771–780.
   PubMed Web of Science ®Google Scholar
• Skov V, Larsen TS, Thomassen M, et al. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res. 2012;36:1387–1392.
   PubMed Web of Science ®Google Scholar
• Skov V, Riley CH, Thomassen M, et al. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma. 2013;54:2269–2273.
   PubMed Web of Science ®Google Scholar
• Belver L, Ferrando AA. Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies. Cancer Discov. 2015;5:234–236.
   PubMed Web of Science ®Google Scholar
• Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5:316–331.
   PubMed Web of Science ®Google Scholar
• Desterke C, Martnaud C, Ruzehaji N, et al. Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis. Mediators Inflamm. 2015; 2015:415024.
   PubMed Web of Science ®Google Scholar
• Riley CH, Jensen MK, Brimnes MK, et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood. 2011;118:2170–2173.
   PubMed Web of Science ®Google Scholar
• Riley CH, Hansen M, Brimnes MK, et al. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α. Eur J Haematol. 2015;94:227–234.
   PubMed Web of Science ®Google Scholar
• Riley CH, Brimnes MK, Hansen M, et al. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol. 2016;97:83–92.
   PubMed Web of Science ®Google Scholar
• Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83:117–158.
   PubMed Web of Science ®Google Scholar
• Bukur J, Jasinski S, Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol. 2012;22:350–358.
   PubMed Web of Science ®Google Scholar
• Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother. 2012;61:249–254.
   PubMed Web of Science ®Google Scholar
• Demanet C, Mulder A, Deneys V, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 2004;103:3122–3130.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4:637–655.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117:4706–4715.
   PubMed Web of Science ®Google Scholar
• Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6:49–58.
   PubMed Web of Science ®Google Scholar
• Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interferon Cytokine Res. 2013;33:145–153.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Giraudier, Cassinat SB. Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone. Leukemia. 2015;30:776–781.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Bjerrum OW, Pallisgaard N, et al. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol. 2008;87:847–850.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Møller MB, de Stricker K, et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology. 2009;14:331–334.
   PubMed Web of Science ®Google Scholar
• Larsen TS, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37:1041–1045.
   PubMed Web of Science ®Google Scholar
• Rank CU, Bjerrum OW, Larsen TS, et al. Minimal residual disease after long-term interferon-alpha2 treatment. A report on hematological, molecular, and histomorphological response patterns in ten patients with essential thrombocythemia and polycythemia vera. Leuk Lymph. 2015. [E-pub ahead of print].
   Web of Science ®Google Scholar
• Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96:1575–1579.
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118:6515–6520.
   PubMed Web of Science ®Google Scholar
• Pettersson H, Knutsen H, Holmberg E, et al. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol. 2015;94:152–156.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. Eur J Haematol. 2015;94:96–98.
   PubMed Web of Science ®Google Scholar
• Gabriele L, Borghi P, Rozera C, et al. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood. 2004;103:980–987.
   PubMed Web of Science ®Google Scholar
• Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol. 2012; 96:1–9.
   PubMed Web of Science ®Google Scholar
• Glauche I, Horn K, Horn M, et al. Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations. Br J Cancer. 2012;106:1742–1752.
   PubMed Web of Science ®Google Scholar
• Brodsky FM, Guagliardi LE. The cell biology of antigen processing and presentation. Annu Rev Immunol. 1991;9:707–744.
   PubMed Web of Science ®Google Scholar
• Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today. 1997;18:89–95.
   PubMedGoogle Scholar
• Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83:117–158.
   PubMed Web of Science ®Google Scholar
• Majumder D, Bandyopadhyay D, Chandra S, et al. Analysis of HLA class Ia transcripts in human leukaemias. Immunogenetics. 2005;57:579–589.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010;24:756–764.
   PubMed Web of Science ®Google Scholar
• Yanai Y, Sanou O, Yamamoto K, et al. The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes. Cancer Lett. 2002;185:173–179.
   PubMed Web of Science ®Google Scholar
• Brouwer RE, van der HP, Schreuder GM, et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol. 2002;63:200–210.
   PubMed Web of Science ®Google Scholar
• Burchert A, Neubauer A. Interferon alpha and T-cell responses in chronic myeloid leukemia. Leuk Lymphoma. 2005;46:167–175.
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89:884–893.
   PubMed Web of Science ®Google Scholar
• Biernacki MA, Marina O, Zhang W, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010;70:906–915.
   PubMed Web of Science ®Google Scholar
• Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity. 2010;43:204–209.
   PubMed Web of Science ®Google Scholar
• Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131–144.
   PubMed Web of Science ®Google Scholar
• Garrido C, Paco L, Romero I, et al. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis. 2012;33:687–693.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Toyota M, Kondo Y, et al. Inflammation-related aberrant patterns of DNA methylation: detection and role in epigenetic deregulation of cancer cell transcriptome. Methods Mol Biol. 2009;512:55–69.
   PubMedGoogle Scholar
• Stenvinkel P, Karimi M, Johansson S, et al. Impact of inflammation on epigenetic DNA methylation – a novel risk factor for cardiovascular disease? J Intern Med. 2007;261:488–499.
   PubMed Web of Science ®Google Scholar
• Kato S, Lindholm B, Stenvinkel P, et al. DNA hypermethylation and inflammatory markers in incident Japanese dialysis patients. Nephron Extra. 2012;2:159–168.
   PubMedGoogle Scholar
• Nie Y, Yang G, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis. 2001;22:1615–1623.
   PubMed Web of Science ®Google Scholar
• Serrano A, Tanzarella S, Lionello I, et al. Rexpression of HLA class I antigens and restoration of antigen-specifi c CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment. Int J Cancer. 2001;94:243–251.
   PubMed Web of Science ®Google Scholar
• Ye Q, Shen Y, Wang X, et al. Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. Tissue Antigens. 2009;75:30–39.
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116:3735–3742.
   PubMed Web of Science ®Google Scholar
• Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008;22:740–747.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150:446–455.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica. 2011;96:1398–1402.
   PubMed Web of Science ®Google Scholar
• Andersen CL, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2013; 162:498–508.
   PubMed Web of Science ®Google Scholar
• Andersen CL, Mortensen NB, Klausen TW, et al. A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis. Haematologica. 2014;99:e5–e7.
   PubMed Web of Science ®Google Scholar